RxDoctor Payments Data

Kimberly Desanctis

Family · Rumford, MENPI 1932614161

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 27.0% of the total. Reporting peaked in 2022 at $530 and has fallen 77.9% since, to $117 in 2025. Among family clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,583in general payments, 2019–2025

Across 86 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$428
  • GSK$369
  • AbbVie$171
  • Lilly USA, LLC$111
  • Takeda Pharmaceuticals U.S.A., Inc.$95
  • Boehringer Ingelheim$67
  • plus $342 from 12 others

What the payments were for

  • Food & beverage$1,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,583 in reported general payments places this provider in the 90th percentile of 545 family providers in Maine.

See all family providers in Maine

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$37,035
Breo ElliptaFluticasone/Vilanterol20$20,202
EliquisApixaban27$18,317
JardianceEmpagliflozin26$15,439
Repatha SyringeEvolocumab11$6,362
Albuterol Sulfate HfaAlbuterol Sulfate40$1,197
Levothyroxine Sodium79$1,181
Atorvastatin Calcium115$999
Bupropion XlBupropion Hcl29$987
Glipizide11$814
Gabapentin19$455
Losartan Potassium51$446
Metoprolol Succinate33$442
Perphenazine16$441
Duloxetine Hcl19$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$428$37,03531 claims
GSKBreo Ellipta$369$20,20220 claims
PfizerEliquis$38$18,31727 claims
Boehringer IngelheimJardiance$67$15,43926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 545 family providers in Maine.

Other family in Rumford

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →